These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 31469852)

  • 1. Implicit and explicit attitudes towards disease-modifying antirheumatic drugs as possible target for improving medication adherence.
    van Heuckelum M; Linn AJ; Vandeberg L; Hebing RCF; van Dijk L; Vervloet M; Flendrie M; Nurmohamed MT; van Dulmen S; van den Bemt BJF; van den Ende CHM
    PLoS One; 2019; 14(8):e0221290. PubMed ID: 31469852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are Health Care Professionals' Implicit and Explicit Attitudes Toward Conventional Disease-Modifying Antirheumatic Drugs Associated With Those of Their Patients?
    van Heuckelum M; Hebing RCF; Vandeberg L; Linn AJ; Flendrie M; Nurmohamed MT; van Dulmen S; van den Ende CHM; van den Bemt BJF
    Arthritis Care Res (Hoboken); 2021 Mar; 73(3):364-373. PubMed ID: 32166901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implicit and Explicit Attitudes Toward Antihypertensive Medications Explain Variation in Pharmacy Refill and Self-Reported Adherence Beyond Traditional Risk Factors: Potential Novel Mechanism Underlying Adherence.
    Craig LS; Peacock E; Mohundro BL; Silver JH; Marsh J; Johnson TC; Kelly PA; Bazzano LA; Cunningham M; Petty RE; Krousel-Wood M
    J Am Heart Assoc; 2021 Mar; 10(6):e018986. PubMed ID: 33660523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Medication Beliefs, Self-efficacy, and Adherence in a Diverse Cohort of Adults with Rheumatoid Arthritis.
    McCulley C; Katz P; Trupin L; Yelin EH; Barton JL
    J Rheumatol; 2018 Dec; 45(12):1636-1642. PubMed ID: 30219761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disentangling Rheumatoid Arthritis Patients' Implicit and Explicit Attitudes toward Methotrexate.
    Linn AJ; Vandeberg L; Wennekers AM; Vervloet M; van Dijk L; van den Bemt BJ
    Front Pharmacol; 2016; 7():233. PubMed ID: 27559311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of adherence to disease modifying anti-rheumatic drugs in White British and South Asian patients with rheumatoid arthritis: a cross sectional study.
    Kumar K; Raza K; Nightingale P; Horne R; Chapman S; Greenfield S; Gill P
    BMC Musculoskelet Disord; 2015 Dec; 16():396. PubMed ID: 26714853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adherence rates and associations with nonadherence in patients with rheumatoid arthritis using disease modifying antirheumatic drugs.
    van den Bemt BJ; van den Hoogen FH; Benraad B; Hekster YA; van Riel PL; van Lankveld W
    J Rheumatol; 2009 Oct; 36(10):2164-70. PubMed ID: 19723906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
    Kim G; Barner JC; Rascati K; Richards K
    Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gaming for Adherence to Medication using Ehealth in Rheumatoid arthritis (GAMER) study: a randomised controlled trial.
    Pouls BPH; Bekker CL; Gundogan F; Hebing RC; van Onzenoort HA; van de Ven LI; Vonkeman HE; Tieben R; Vriezekolk JE; van Dulmen S; Van den Bemt B
    RMD Open; 2022 Nov; 8(2):. PubMed ID: 36410776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pilot study assessing the novel use of musculoskeletal ultrasound in patients with rheumatoid arthritis to improve patient attitudes and adherence to medication.
    Joplin SK; van der Zwan R; Bagga H; Joshua F; Wong PK
    Int J Rheum Dis; 2016 Jul; 19(7):658-64. PubMed ID: 24839920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews.
    Scott DL; Ibrahim F; Farewell V; O'Keeffe AG; Ma M; Walker D; Heslin M; Patel A; Kingsley G
    Health Technol Assess; 2014 Oct; 18(66):i-xxiv, 1-164. PubMed ID: 25351370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study.
    Smolen JS; Gladman D; McNeil HP; Mease PJ; Sieper J; Hojnik M; Nurwakagari P; Weinman J
    RMD Open; 2019; 5(1):e000585. PubMed ID: 30713716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the utility of visual feedback in the treatment of early rheumatoid arthritis patients: a pilot study.
    El Miedany Y; El Gaafary M; Palmer D
    Rheumatol Int; 2012 Oct; 32(10):3061-8. PubMed ID: 21909946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.
    Oladapo A; Barner JC; Lawson KA; Novak S; Rascati KL; Richards KM; Harrison DJ
    J Manag Care Spec Pharm; 2014 Jul; 20(7):657-67. PubMed ID: 24967519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of patients at risk of non-adherence to oral antirheumatic drugs in rheumatoid arthritis using the Compliance Questionnaire in Rheumatology: an ARCO sub-study.
    Marras C; Monteagudo I; Salvador G; de Toro FJ; Escudero A; Alegre-Sancho JJ; Raya E; Ortiz A; Carmona L; Mestre Y; Cea-Calvo L; Calvo-Alén J
    Rheumatol Int; 2017 Jul; 37(7):1195-1202. PubMed ID: 28516236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in Disease-Modifying Antirheumatic Drug Treatment for Patients With Rheumatoid Arthritis in the US During the COVID-19 Pandemic: A Three-Month Observational Study.
    Michaud K; Pedro S; Wipfler K; Agarwal E; Katz P
    Arthritis Care Res (Hoboken); 2021 Sep; 73(9):1322-1331. PubMed ID: 33787086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The beliefs of rheumatoid arthritis patients in their subcutaneous biological drug: strengths and areas of concern.
    Cea-Calvo L; Raya E; Marras C; Salman-Monte TC; Ortiz A; Salvador G; Monteagudo I; Carmona L; Fernandez S; Arteaga MJ; Calvo-Allén J
    Rheumatol Int; 2018 Sep; 38(9):1735-1740. PubMed ID: 29959469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High degree of nonadherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
    Rauscher V; Englbrecht M; van der Heijde D; Schett G; Hueber AJ
    J Rheumatol; 2015 Mar; 42(3):386-90. PubMed ID: 25593229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
    Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
    Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonadherence to disease modifying antirheumatic drugs in the first year after diagnosis: comparing three adherence measures in early arthritis patients.
    Pasma A; den Boer E; van 't Spijker A; Timman R; van den Bemt B; Busschbach JJ; Hazes JM
    Rheumatology (Oxford); 2016 Oct; 55(10):1812-9. PubMed ID: 27354686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.